Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials

Citation:

Fukuokaya W, Mori K, Yanagisawa T, Akazawa K, Shimomura T, Kimura T. Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials. Prostate Cancer Prostatic Dis. 2023 Jul 18. doi: 10.1038/s41391-023-00695-x. Epub ahead of print. PMID: 37464102.